CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
US4162940A
(en)
|
1977-03-31 |
1979-07-31 |
Takeda Chemical Industries, Ltd. |
Method for producing Antibiotic C-15003 by culturing nocardia
|
US4169888A
(en)
|
1977-10-17 |
1979-10-02 |
The Upjohn Company |
Composition of matter and process
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4263294A
(en)
|
1978-11-20 |
1981-04-21 |
Takeda Chemical Industries, Ltd. |
Maytansinoids, pharmaceutical compositions thereof and method of use thereof
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
JPS5622790A
(en)
|
1979-07-31 |
1981-03-03 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
US4342566A
(en)
|
1980-02-22 |
1982-08-03 |
Scripps Clinic & Research Foundation |
Solid phase anti-C3 assay for detection of immune complexes
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
US4413132A
(en)
|
1980-11-18 |
1983-11-01 |
The Upjohn Company |
Antibiotic CC-1065 indoline intermediates
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
US4671958A
(en)
|
1982-03-09 |
1987-06-09 |
Cytogen Corporation |
Antibody conjugates for the delivery of compounds to target sites
|
US4867973A
(en)
|
1984-08-31 |
1989-09-19 |
Cytogen Corporation |
Antibody-therapeutic agent conjugates
|
FR2523445A1
(fr)
|
1982-03-17 |
1983-09-23 |
Sanofi Sa |
Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
|
US4418064A
(en)
|
1982-09-29 |
1983-11-29 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
IL74201A0
(en)
|
1984-01-30 |
1985-04-30 |
Icrf Patents Limited |
Polypeptides for the detection and control of mammalian cell growth
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US5851526A
(en)
|
1985-04-19 |
1998-12-22 |
Ludwig Institute For Cancer Research |
Methods of treating colon cancer utilizing tumor-specific antibodies
|
US5776093A
(en)
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US4997913A
(en)
|
1986-06-30 |
1991-03-05 |
Oncogen |
pH-sensitive immunoconjugates and methods for their use in tumor therapy
|
IN165717B
(es)
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US5034223A
(en)
|
1986-10-09 |
1991-07-23 |
Neorx Corporation |
Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
|
USRE38008E1
(en)
|
1986-10-09 |
2003-02-25 |
Neorx Corporation |
Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
|
US5047324A
(en)
|
1986-12-09 |
1991-09-10 |
Miles Inc. |
Substantially pure enzyme-antibody conjugate preparations
|
US5332837A
(en)
|
1986-12-19 |
1994-07-26 |
The Upjohn Company |
CC-1065 analogs
|
US4952394A
(en)
|
1987-11-23 |
1990-08-28 |
Bristol-Myers Company |
Drug-monoclonal antibody conjugates
|
US5563250A
(en)
|
1987-12-02 |
1996-10-08 |
Neorx Corporation |
Cleavable conjugates for the delivery and release of agents in native form
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク,インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
US4937183A
(en)
|
1988-02-03 |
1990-06-26 |
Cytogen Corporation |
Method for the preparation of antibody-fragment conjugates
|
IL89220A
(en)
|
1988-02-11 |
1994-02-27 |
Bristol Myers Squibb Co |
Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them
|
EP0329184A3
(en)
|
1988-02-19 |
1990-05-23 |
Neorx Corporation |
Antimers and antimeric conjugation
|
US6010902A
(en)
|
1988-04-04 |
2000-01-04 |
Bristol-Meyers Squibb Company |
Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
|
US5028697A
(en)
|
1988-08-08 |
1991-07-02 |
Eli Lilly And Company |
Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
|
WO1990002746A1
(en)
|
1988-09-12 |
1990-03-22 |
The Upjohn Company |
Novel cc-1065 analogs having two cpi subunits
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
US5171563A
(en)
|
1988-09-30 |
1992-12-15 |
Neorx Corporation |
Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
|
DE68909416T2
(de)
|
1988-10-12 |
1994-03-24 |
Centocor Inc |
Radiotherapeutische immunokonjugate, etikettiert mit iod-125.
|
US5217713A
(en)
|
1988-12-27 |
1993-06-08 |
Takeda Chemical Industries, Ltd. |
Cytotoxic bispecific monoclonal antibody, its production and use
|
CA2006408A1
(en)
|
1988-12-27 |
1990-06-27 |
Susumu Iwasa |
Bispecific monoclonal antibody, its production and use
|
US5013547A
(en)
|
1989-02-07 |
1991-05-07 |
Erbamont, Inc. |
Anticancer drug - antibody conjugates and method for preparing same
|
US6020145A
(en)
|
1989-06-30 |
2000-02-01 |
Bristol-Myers Squibb Company |
Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
|
US5980896A
(en)
|
1989-06-30 |
1999-11-09 |
Bristol-Myers Squibb Company |
Antibodies reactive with human carcinomas
|
US5332567A
(en)
|
1989-08-24 |
1994-07-26 |
Immunomedics |
Detection and treatment of infections with immunoconjugates
|
ATE135373T1
(de)
|
1989-09-08 |
1996-03-15 |
Univ Johns Hopkins |
Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5459061A
(en)
|
1990-01-26 |
1995-10-17 |
W. Alton Jones Cell Science Center, Inc. |
Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
|
CA2076347C
(en)
|
1990-02-20 |
1996-11-26 |
Ravinder K. Gupta |
Improved antibody-enzyme direct conjugates and method of making same
|
AU7774391A
(en)
|
1990-04-20 |
1991-11-11 |
Ludwig Institute For Cancer Research |
Aberrant, epidermal growth factor receptor dna, rna and protein forms and method
|
EP0527189A1
(en)
|
1990-04-25 |
1993-02-17 |
PHARMACIA & UPJOHN COMPANY |
Novel cc-1065 analogs
|
US6248332B1
(en)
|
1990-10-05 |
2001-06-19 |
Medarex, Inc. |
Targeted immunostimulation with bispecific reagents
|
JPH04334377A
(ja)
|
1990-12-31 |
1992-11-20 |
Akzo Nv |
酸−不安定性リンカー分子
|
JP3854306B2
(ja)
|
1991-03-06 |
2006-12-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
ヒト化及びキメラモノクローナル抗体
|
RU2139351C1
(ru)
|
1991-04-25 |
1999-10-10 |
Чугаи Сейяку Кабусики Кайся |
Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
|
US6797492B2
(en)
|
1991-05-17 |
2004-09-28 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
WO1993011161A1
(en)
|
1991-11-25 |
1993-06-10 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
ES2149768T3
(es)
|
1992-03-25 |
2000-11-16 |
Immunogen Inc |
Conjugados de agentes enlazantes de celulas derivados de cc-1065.
|
EP0586002B1
(en)
|
1992-08-18 |
2000-01-19 |
CENTRO de IMMUNOLOGIA MOLECULAR |
Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
WO1994013804A1
(en)
|
1992-12-04 |
1994-06-23 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US5674977A
(en)
|
1993-02-05 |
1997-10-07 |
The Ontario Cancer Institute |
Branched synthetic peptide conjugate
|
US5556623A
(en)
|
1993-03-30 |
1996-09-17 |
Eli Lilly And Company |
Antibody-drug conjugates
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5443953A
(en)
|
1993-12-08 |
1995-08-22 |
Immunomedics, Inc. |
Preparation and use of immunoconjugates
|
AU692239B2
(en)
|
1994-03-07 |
1998-06-04 |
Medarex, Inc. |
Bispecific molecules having clinical utilities
|
PT699237E
(pt)
|
1994-03-17 |
2003-07-31 |
Merck Patent Gmbh |
Fvs de cadeia anti-egfr e anticorpos anti-egfr
|
CU22615A1
(es)
|
1994-06-30 |
2000-02-10 |
Centro Inmunologia Molecular |
Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
|
US5612474A
(en)
|
1994-06-30 |
1997-03-18 |
Eli Lilly And Company |
Acid labile immunoconjugate intermediates
|
US5911995A
(en)
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
JP4620808B2
(ja)
|
1994-11-28 |
2011-01-26 |
トーマス・ジェファーソン・ユニバーシティ |
突然変異上皮成長因子受容体を標的とする試薬および方法
|
WO1996040662A2
(en)
|
1995-06-07 |
1996-12-19 |
Cellpro, Incorporated |
Aminooxy-containing linker compounds and their application in conjugates
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
WO1996040210A1
(en)
|
1995-06-07 |
1996-12-19 |
Imclone Systems Incorporated |
Antibody and antibody fragments for inhibiting the growth of tumors
|
CA2233936A1
(en)
|
1995-10-03 |
1997-04-10 |
The Scripps Research Institute |
Cbi analogs of cc-1065 and the duocarmycins
|
US6699715B1
(en)
|
1995-11-30 |
2004-03-02 |
Bristol-Myers Squibb Co. |
Modified sFv molecules which mediate adhesion between cells and uses thereof
|
PT871490E
(pt)
|
1995-12-22 |
2003-07-31 |
Bristol Myers Squibb Co |
Ligantes de hidrazona ramificada
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
US5708156A
(en)
|
1996-05-31 |
1998-01-13 |
Ilekis; John V. |
Epidermal growth factor receptor-like gene product and its uses
|
CA2255703A1
(en)
|
1996-05-31 |
1997-12-04 |
Dale L. Boger |
Analogs of cc-1065 and the duocarmycins
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
US5942602A
(en)
|
1997-02-13 |
1999-08-24 |
Schering Aktiengessellschaft |
Growth factor receptor antibodies
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
AU754083B2
(en)
|
1997-05-22 |
2002-11-07 |
Scripps Research Institute, The |
Analogs of duocarmycin and CC-1065
|
AU756721B2
(en)
|
1997-10-14 |
2003-01-23 |
Scripps Research Institute, The |
iso-CBI and iso-CI analogs of CC-1065 and the duocarmycins
|
IL136489A0
(en)
|
1997-12-08 |
2001-06-14 |
Scripps Research Inst |
Synthesis of cc-1065/duocarmycin analogs
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
US20030224001A1
(en)
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
JP2002512776A
(ja)
|
1998-04-28 |
2002-05-08 |
スミスクライン・ビーチャム・コーポレイション |
免疫原性の低下したモノクローナル抗体
|
US6962702B2
(en)
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
US20030215387A1
(en)
|
1998-09-04 |
2003-11-20 |
Peter Harrison |
Bifunctional antibodies and their use in targeting anti-tumour agents
|
IL146480A0
(en)
|
1999-05-14 |
2002-07-25 |
Imclone Systems Inc |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US7303749B1
(en)
|
1999-10-01 |
2007-12-04 |
Immunogen Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
CA2385528C
(en)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
DE60032633T2
(de)
|
1999-11-24 |
2007-10-04 |
Immunogen Inc., Cambridge |
Zytotoxische mittel, die taxane enthalten und ihre therapeutische anwendung
|
AU767394C
(en)
|
1999-12-29 |
2005-04-21 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
AU2001239857B9
(en)
|
2000-02-25 |
2006-07-27 |
Duke University |
Anti-EGFRvIII SCFVS with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
|
US20010046686A1
(en)
|
2000-03-10 |
2001-11-29 |
Wong Albert J. |
Sensitive detection of wild-type and mutant EGFR by specific ELISA assays in any biological sample
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
SI2857516T1
(sl)
|
2000-04-11 |
2017-09-29 |
Genentech, Inc. |
Multivalentna protitelesa in njihove uporabe
|
EP1280771B1
(de)
|
2000-05-02 |
2004-10-13 |
Tietze, Lutz F., Prof. Dr. |
Neue prodrugs von 6-hydroxy-2,3-dihydro-1h-indolen, 5-hydroxy-1,2-dihydro-3h-pyrrolo 3,2-e]indolen und 5-hydroxy-1,2-dihydro-3h-benzo e]indolen sowie von 6-hydroxy-1,2,3,4-tetrahydro-benzo f]chinolin-derivaten für eine selektive krebstherapie
|
CN102698265A
(zh)
|
2000-05-19 |
2012-10-03 |
杰南技术公司 |
用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验
|
AUPQ841800A0
(en)
|
2000-06-28 |
2000-07-20 |
Biomolecular Research Institute Limited |
Truncated egf receptor
|
EP1311291A4
(en)
|
2000-08-09 |
2007-07-25 |
Imclone Systems Inc |
TREATMENT OF HYPERPROLIFERATIVE DISEASES USING EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
AR030612A1
(es)
|
2000-09-12 |
2003-08-27 |
Smithkline Beecham Corp |
Procedimiento e intermedios
|
ES2254492T3
(es)
|
2000-09-19 |
2006-06-16 |
Moses Lee |
Composiciones y procedimientos de uso de analogos aquirales de cc-1065 y de duocarmicinas.
|
DE10048417A1
(de)
|
2000-09-29 |
2002-04-11 |
Roche Diagnostics Gmbh |
Verbindungen mit verzweigtem Linker
|
US7132511B2
(en)
|
2001-02-19 |
2006-11-07 |
Merck Patent Gmbh |
Modified anti-EGFR antibodies with reduced immunogenicity
|
US20080008704A1
(en)
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
US20020156274A1
(en)
|
2001-03-16 |
2002-10-24 |
Terfloth Gerald J. |
Process for preparing maytansinol
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US20030083263A1
(en)
|
2001-04-30 |
2003-05-01 |
Svetlana Doronina |
Pentapeptide compounds and uses related thereto
|
RU2003134180A
(ru)
|
2001-05-08 |
2005-02-10 |
Мерк Патент ГмбХ (DE) |
Комбинированная терапия, использующая антитела к egfr и антигормональные средства
|
ATE446317T1
(de)
|
2001-05-11 |
2009-11-15 |
Ludwig Inst For Cancer Res Ltd |
Spezifische bindungsproteine und ihre verwendung
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
EP1434778A4
(en)
|
2001-05-31 |
2005-07-13 |
Medarex Inc |
CYTOTOXINS, PROMEDICAMENTS, BINDERS AND STABILIZERS USEFUL THEREFOR
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
MXPA03011365A
(es)
|
2001-06-13 |
2005-03-07 |
Genmab As |
Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr).
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
US20050107595A1
(en)
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
WO2003014159A1
(en)
|
2001-08-03 |
2003-02-20 |
Commonwealth Scientific And Industrial Research Organisation |
Methods of screening based on the egf receptor crystal structure
|
US20030109682A1
(en)
|
2001-09-07 |
2003-06-12 |
Daniel Santi |
Maytansines and maytansine conjugates
|
US20050014700A1
(en)
|
2001-09-07 |
2005-01-20 |
Boger Dale L. |
Cbi analogues of cc-1065 and the duocarmycins
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
US20060084141A1
(en)
|
2001-11-21 |
2006-04-20 |
Floss Heinz G |
Biosynthetic gene cluster for the maytansinoid antitumor agent ansamitocin
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
WO2003057163A2
(en)
|
2002-01-03 |
2003-07-17 |
Smithkline Beecham Corporation |
Methods for preparing immunoconjugates
|
US6790954B2
(en)
|
2002-01-29 |
2004-09-14 |
Immunogen, Inc. |
Mutant Actinosynnema pretiosum strain with increased maytansinoid production
|
ATE509032T1
(de)
|
2002-02-13 |
2011-05-15 |
Ludwig Inst For Cancer Res Ltd |
Chimerizierte gm-csf antikörper
|
WO2003080569A2
(en)
|
2002-03-19 |
2003-10-02 |
The Penn State Research Foundation |
Egfr ligands and methods of use
|
US6534660B1
(en)
|
2002-04-05 |
2003-03-18 |
Immunogen, Inc. |
CC-1065 analog synthesis
|
US6756397B2
(en)
|
2002-04-05 |
2004-06-29 |
Immunogen, Inc. |
Prodrugs of CC-1065 analogs
|
US20050276812A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
JP2005525423A
(ja)
|
2002-05-13 |
2005-08-25 |
スミスクライン・ビーチャム・コーポレイション |
メイタンシノールの調製方法
|
US6596757B1
(en)
|
2002-05-14 |
2003-07-22 |
Immunogen Inc. |
Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
|
US20040033543A1
(en)
|
2002-05-20 |
2004-02-19 |
Gisela Schwab |
Treatment of renal carcinoma using antibodies against the EGFr
|
JP2006512895A
(ja)
|
2002-06-28 |
2006-04-20 |
ドマンティス リミテッド |
リガンド
|
ES2556641T3
(es)
|
2002-07-31 |
2016-01-19 |
Seattle Genetics, Inc. |
Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
CA2494074A1
(en)
|
2002-08-02 |
2004-02-12 |
Immunogen, Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
US6913748B2
(en)
|
2002-08-16 |
2005-07-05 |
Immunogen, Inc. |
Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
|
MXPA05001933A
(es)
|
2002-08-19 |
2005-04-28 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
SI1549344T1
(sl)
|
2002-10-10 |
2015-05-29 |
Merck Patent Gmbh |
FARMACEVTSKI SESTAVKI PROTI RECEPTORJEM ErbB1
|
EP1560599A1
(en)
|
2002-11-14 |
2005-08-10 |
Syntarga B.V. |
Prodrugs built as multiple self-elimination-release spacers
|
US20040147428A1
(en)
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
US20040202666A1
(en)
|
2003-01-24 |
2004-10-14 |
Immunomedics, Inc. |
Anti-cancer anthracycline drug-antibody conjugates
|
EP1622941A2
(en)
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
CA2450289A1
(en)
|
2003-03-20 |
2005-05-19 |
Imclone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
US7432088B2
(en)
|
2003-05-08 |
2008-10-07 |
Immunogen Inc. |
Methods for the production of ansamitocins
|
US20050026987A1
(en)
|
2003-05-13 |
2005-02-03 |
The Scripps Research Institute |
CBI analogues of the duocarmycins and CC-1065
|
CA2737127C
(en)
|
2003-05-14 |
2016-07-26 |
Immunogen, Inc. |
Maytansinoid-antibody conjugate compositions
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
EP1638606B1
(en)
|
2003-06-27 |
2016-01-06 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
SG195524A1
(en)
|
2003-11-06 |
2013-12-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
US20050142133A1
(en)
|
2003-12-03 |
2005-06-30 |
Xencor, Inc. |
Optimized proteins that target the epidermal growth factor receptor
|
KR100956913B1
(ko)
|
2003-12-19 |
2010-05-11 |
제넨테크, 인크. |
치료제로서 유용한 일가 항체 단편
|
US20050214310A1
(en)
|
2004-01-23 |
2005-09-29 |
Seattle Genetics, Inc. |
Melphalan prodrugs
|
US7767792B2
(en)
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
WO2005082023A2
(en)
|
2004-02-23 |
2005-09-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
ES2533695T3
(es)
|
2004-03-02 |
2015-04-14 |
Seattle Genetics, Inc. |
Anticuerpos cargados parcialmente y métodos para su conjugación
|
TW200533339A
(en)
|
2004-03-16 |
2005-10-16 |
Bristol Myers Squibb Co |
Therapeutic synergy of anti-cancer compounds
|
EP2053062A1
(en)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
ES2741573T3
(es)
|
2004-03-31 |
2020-02-11 |
Massachusetts Gen Hospital |
Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
|
WO2005099754A2
(en)
|
2004-04-14 |
2005-10-27 |
The Ohio State University Research Foundation |
Maytansinoid analogs as antitumor agents
|
US7691962B2
(en)
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
NZ550934A
(en)
|
2004-05-19 |
2010-05-28 |
Medarex Inc |
Chemical linkers and conjugates thereof
|
JP2008504809A
(ja)
|
2004-06-04 |
2008-02-21 |
ジェネンテック・インコーポレーテッド |
Egfr突然変異
|
AU2005286607B2
(en)
|
2004-09-23 |
2011-01-27 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
JP2008519863A
(ja)
|
2004-11-12 |
2008-06-12 |
シアトル ジェネティクス インコーポレイティッド |
N末端にアミノ安息香酸単位を有するオーリスタチン
|
JP2008521828A
(ja)
|
2004-11-29 |
2008-06-26 |
シアトル ジェネティックス, インコーポレイテッド |
操作された抗体およびイムノコンジュゲート
|
US20070134243A1
(en)
|
2004-12-01 |
2007-06-14 |
Gazzard Lewis J |
Antibody drug conjugates and methods
|
EP1688415A1
(en)
|
2004-12-07 |
2006-08-09 |
Aventis Pharma S.A. |
Cytotoxic agents comprising new C-2 modified taxanes
|
WO2006063042A2
(en)
|
2004-12-07 |
2006-06-15 |
Genentech, Inc. |
Selecting patients for therapy with a her inhibitor
|
EP1669358A1
(en)
|
2004-12-07 |
2006-06-14 |
Aventis Pharma S.A. |
Cytotoxic agents comprising new taxanes
|
US7301019B2
(en)
|
2005-01-21 |
2007-11-27 |
Immunogen, Inc. |
Method for the preparation of maytansinoid esters
|
CA2597407C
(en)
|
2005-02-11 |
2013-09-10 |
Immunogen, Inc. |
Process for preparing stable drug conjugates
|
AU2006232378A1
(en)
|
2005-04-01 |
2006-10-12 |
Amgen Inc. |
Epidermal growth factor receptor gene copy number
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
ES2708763T3
(es)
|
2005-07-07 |
2019-04-11 |
Seattle Genetics Inc |
Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
|
US8871720B2
(en)
|
2005-07-07 |
2014-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
|
EP4026840A1
(en)
|
2005-07-18 |
2022-07-13 |
Seagen Inc. |
Beta-glucuronide-linker drug conjugates
|
MX336033B
(es)
|
2005-08-03 |
2016-01-07 |
Immunogen Inc |
Formulaciones de inmunoconjugado.
|
EP1909846B1
(en)
|
2005-08-05 |
2018-12-26 |
Syntarga B.V. |
Triazole-containing releasable linkers, conjugates comprising the same and processes for their preparation
|
WO2007021674A2
(en)
|
2005-08-09 |
2007-02-22 |
Millennium Pharmaceuticals, Inc. |
Method of acylating maytansinol with chiral amino acids
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
AU2006283726C1
(en)
|
2005-08-24 |
2015-05-07 |
Immunogen, Inc. |
Process for preparing maytansinoid antibody conjugates
|
CA2623652C
(en)
|
2005-09-26 |
2013-11-26 |
Medarex, Inc. |
Antibody-drug conjugates and methods of use
|
AU2006305842B2
(en)
|
2005-10-26 |
2011-11-03 |
E. R. Squibb & Sons, L.L.C. |
Methods and compounds for preparing CC-1065 analogs
|
AU2006311485B2
(en)
|
2005-11-08 |
2012-09-27 |
Immunogen, Inc. |
Processes for preparation of maytansinol
|
WO2007059404A2
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
DK1948180T3
(da)
|
2005-11-11 |
2013-05-27 |
Boehringer Ingelheim Int |
Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
|
JP2009515878A
(ja)
|
2005-11-12 |
2009-04-16 |
イーライ リリー アンド カンパニー |
抗egfr抗体
|
EA015173B1
(ru)
|
2006-01-04 |
2011-06-30 |
Мерк Патент Гмбх |
Комбинированная терапия с использованием антител к egfr и her2
|
MX2008009956A
(es)
|
2006-02-02 |
2008-12-12 |
Syntarga Bv |
Analogos de cc-1065 solubles en agua y sus conjugados.
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
WO2007103288A2
(en)
|
2006-03-02 |
2007-09-13 |
Seattle Genetics, Inc. |
Engineered antibody drug conjugates
|
EP1832577A1
(en)
|
2006-03-07 |
2007-09-12 |
Sanofi-Aventis |
Improved prodrugs of CC-1065 analogs
|
WO2007106503A2
(en)
|
2006-03-13 |
2007-09-20 |
Osi Pharmaceuticals, Inc. |
Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
|
US20090280503A1
(en)
|
2006-09-15 |
2009-11-12 |
James Fiore |
Method for detecting and treating skin disorders
|
EP2084527A4
(en)
|
2006-11-02 |
2011-07-27 |
Seattle Genetics Inc |
METHOD FOR TREATING NEOPLASIA, AUTOIMMUNE AND INFLAMMATORY DISEASES
|
US7790164B2
(en)
|
2006-11-14 |
2010-09-07 |
Van Andel Research Institute |
Fragments of antibodies to epidermal growth factor receptor and methods of their use
|
AU2007353412A1
(en)
|
2006-11-21 |
2008-11-20 |
Fox Chase Cancer Center |
Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
|
JP5276017B2
(ja)
|
2007-01-25 |
2013-08-28 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Egfr変異体仲介性疾患の治療における抗egfr抗体の使用
|
CN101688229B
(zh)
|
2007-03-15 |
2013-06-12 |
路德维格癌症研究所 |
包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
|
WO2008154927A1
(en)
|
2007-06-21 |
2008-12-24 |
Genmab A/S |
Novel methods for treating egfr-associated tumors
|
EP2173739B1
(en)
|
2007-08-01 |
2013-07-31 |
Syntarga B.V. |
Substituted cc-1065 analogs and their conjugates
|
CN101896503B
(zh)
|
2007-08-14 |
2018-05-22 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
US20090269343A1
(en)
|
2008-04-11 |
2009-10-29 |
Duke University |
Dual Specific Immunotoxin for Brain Tumor Therapy
|
PL2281006T3
(pl)
|
2008-04-30 |
2018-01-31 |
Immunogen Inc |
Środki łączące i ich zastosowania
|
CN102112494A
(zh)
|
2008-06-03 |
2011-06-29 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
SG10201706294VA
(en)
|
2009-02-05 |
2017-09-28 |
Immunogen Inc |
Novel benzodiazepine derivatives
|
AU2010242840B2
(en)
|
2009-05-01 |
2014-04-17 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
EP2481754B1
(en)
|
2009-09-22 |
2014-06-18 |
Shanghai Yijie Biotechnology Co., Ltd |
Specific binding proteins and uses thereof
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
US10886995B2
(en)
*
|
2018-11-02 |
2021-01-05 |
Qualcomm Incorporated |
Beam management signaling
|